Compare
Inspire Medical Systems, Inc. vs Tandem Diabetes Care Inc vs iRhythm Holdings, Inc. vs Haemonetics Corp
| Latest fiscal year | Inspire Medical Systems, Inc. INSP | Tandem Diabetes Care Inc TNDM | iRhythm Holdings, Inc. IRTC | Haemonetics Corp HAE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-28 |
| Revenue | $911.98M | $1.01B | $747.14M | $1.33B |
| Revenue growth (YoY) | +13.6% | +7.9% | +26.2% | -2.0% |
| Gross margin | 85.4% | 53.8% | 70.6% | 59.0% |
| Operating margin | 5.6% | -18.5% | -7.7% | 11.7% |
| Net margin | 15.9% | -20.2% | -6.0% | 7.3% |
| Net income | $145.42M | -$204.71M | -$44.55M | $97.31M |
| EPS (Diluted) | $4.89 | -$3.04 | -$1.39 | $2.05 |
| Operating cash flow | $116.98M | -$9.72M | $80.86M | $293.22M |
| Free cash flow | $78.48M | -$29.67M | $34.52M | $260.44M |
| Cash & equivalents | $104.81M | $90.63M | $236.01M | $245.44M |
| Total assets | $907.32M | $881.11M | $1.02B | $2.40B |
| Total liabilities | $126.16M | $725.94M | $867.30M | n/a |
| Shareholders' equity | $781.16M | $155.17M | $152.75M | $796.32M |
| Return on year-end equity | 18.6% | -131.9% | -29.2% | 12.2% |
| Shares outstanding | 28.58M | 68.29M | 32.30M | 45.25M |
Revenue, most recent five fiscal years
| Fiscal year | Inspire Medical Systems, Inc. | Tandem Diabetes Care Inc | iRhythm Holdings, Inc. | Haemonetics Corp |
|---|---|---|---|---|
| Latest | $911.98M Ended 2025-12-31 | $1.01B Ended 2025-12-31 | $747.14M Ended 2025-12-31 | $1.33B Ended 2026-03-28 |
| 1 year earlier | $802.80M Ended 2024-12-31 | $940.20M Ended 2024-12-31 | $591.84M Ended 2024-12-31 | $1.36B Ended 2025-03-29 |
| 2 years earlier | $624.80M Ended 2023-12-31 | $747.72M Ended 2023-12-31 | $492.68M Ended 2023-12-31 | $1.31B Ended 2024-03-30 |
| 3 years earlier | $407.86M Ended 2022-12-31 | $801.22M Ended 2022-12-31 | $410.92M Ended 2022-12-31 | $1.17B Ended 2023-04-01 |
| 4 years earlier | $233.39M Ended 2021-12-31 | $702.80M Ended 2021-12-31 | $322.82M Ended 2021-12-31 | $993.20M Ended 2022-04-02 |